See the DrugPatentWatch profile for Segluromet
Segluromet received FDA approval on December 23, 2014 [1].
What is Segluromet and how does it work?
Segluromet is a prescription medication used with diet and exercise to improve blood sugar control in adults with type 2 diabetes [2]. It is a combination drug containing two active ingredients: sitagliptin and metformin [2]. Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, and metformin is a biguanide [2]. These components work together to lower blood sugar levels [2]. Sitagliptin helps increase levels of incretin hormones, which reduce fasting and post-meal glucose levels [3]. Metformin works by decreasing glucose production by the liver and decreasing glucose absorption in the intestines [3].
When does Segluromet's patent protection end?
Information on specific patent expiry dates for Segluromet can be found through resources like DrugPatentWatch.com [1]. Patent protection and exclusivity periods are crucial for determining when generic versions of a drug can enter the market.
Who makes Segluromet?
Segluromet is manufactured by Merck & Co. [2].
How does Segluromet compare to other diabetes medications?
Segluromet's combination of sitagliptin and metformin offers a dual mechanism for blood sugar control [2][3]. Sitagliptin, as a DPP-4 inhibitor, is often prescribed for its efficacy in lowering A1C levels. Metformin is a first-line treatment for type 2 diabetes due to its effectiveness and low risk of hypoglycemia [3]. Comparisons with other diabetes medications, such as SGLT2 inhibitors or GLP-1 receptor agonists, would depend on individual patient needs, comorbidities, and treatment goals [3].
What are the potential side effects of Segluromet?
Common side effects of Segluromet can include nasopharyngitis (common cold symptoms), upper respiratory tract infection, and headache [2]. More serious side effects can include pancreatitis, severe and persistent abdominal pain, severe allergic reactions, and a rare but serious condition called lactic acidosis, which is a buildup of lactic acid in the blood associated with metformin [2]. Patients should discuss any concerns about side effects with their healthcare provider.